Fresh from gobbling up a £1.9bn purchase of Boots' over-the-counter medicines business, Reckitt Benckiser may now be eying an even bigger dish; the $14bn (£8bn) consumer healthcare business of Pfizer.
Pfizer announced earlier this month that it would explore "strategic alternatives", including a sale or spin-off of the business, which is home to a host of household names such as Rogaine, Listerine and Sudafed.
It has hired Lazard to run the auction.
Source: The Independent
No comments:
Post a Comment